CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28

Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant

New York, NY – September 12, 2023 — The Muscular

CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program

The Charcot-Marie-Tooth Association July 17 hailed the news that global

Development of Treatments for CMT2D

Professor Robert Burgess and his team at The Jackson Laboratory

CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients

The Charcot-Marie-Tooth Association (CMTA) announced the results of a review

Development of Advanced Research Diagnostic Capabilities for the CMT Community

CMT is a genetic disease caused by distinct changes in

Studying Neurodegeneration in CMT1X Mouse Model

In people with CMT1X cell-to-cell communication within the peripheral nervous

Establishing gene therapy strategies for CMT2E

CMT2E is caused by dominant or recessive mutations in the

CMTA to attend the annual BIO partnering conference in Boston

The CMTA is a global leader in the acceleration of

CMTA Adds Science Writer Kenneth Raymond to Team

On April 17, 2023, the Charcot-Marie-Tooth Association welcomed Kenneth Raymond